Protein N-Terminal Processing: Substrate Specificity of *Escherichia coli* and Human Methionine Aminopeptidases[†]

Qing Xiao,[‡] Feiran Zhang,[§] Benjamin A. Nacev,[§] Jun O. Liu,[§] and Dehua Pei*,[‡]

[‡]Department of Chemistry, The Ohio State University, 100 West 18th Avenue, Columbus, Ohio 43210, and [§]Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, 725 North Wolfe Street, Baltimore, Maryland 21205

Received April 11, 2010; Revised Manuscript Received June 1, 2010

ABSTRACT: Methionine aminopeptidase (MetAP) catalyzes the hydrolytic cleavage of the N-terminal methionine from newly synthesized polypeptides. The extent of removal of methionyl from a protein is dictated by its N-terminal peptide sequence. Earlier studies revealed that MetAPs require amino acids containing small side chains (e.g., Gly, Ala, Ser, Cys, Pro, Thr, and Val) as the Pl' residue, but their specificity at positions P2' and beyond remains incompletely defined. In this work, the substrate specificities of *Escherichia coli* MetAP1, human MetAP1, and human MetAP2 were systematically profiled by screening against a combinatorial peptide library and kinetic analysis of individually synthesized peptide substrates. Our results show that although all three enzymes require small residues at the P1' position, they have differential tolerance for Val and Thr at this position. The catalytic activity of human MetAP2 toward Met-Val peptides is consistently 2 orders of magnitude higher than that of MetAP1, suggesting that MetAP2 is responsible for processing proteins containing N-terminal Met-Val and Met-Thr sequences in vivo. At positions P2'-P5', all three MetAPs have broad specificity but are poorly active toward peptides containing a proline at the P2' position. In addition, the human MetAPs disfavor acidic residues at the P2'-P5' positions. The specificity data have allowed us to formulate a simple set of rules that can reliably predict the N-terminal processing of *E. coli* and human proteins.

Ribosomal protein synthesis is universally initiated with methionine (in eukaryotic cytoplasm) or N-formylmethionine (in prokaryotes, mitochondria, and chloroplasts). During protein maturation, the N-formyl group is removed by peptide deformylase, leaving methionine with a free NH_2 group (1). Subsequently, the initiator methionine is removed from many but not all of the proteins by methionine aminopeptidase(s) (MetAPs).¹ For example, in a cytosolic extract of Escherichia coli, only 40% of the polypeptides retain the initiator methionine, whereas the majority of the polypeptides display alanine, serine, or threonine at their N-termini (2). There are two types of MetAPs, MetAP1 and MetAP2. While eubacteria have only MetAP1 and archaea have only MetAP2, eukaryotes, including yeast, have both MetAP1 and MetAP2 in the cytoplasm and MetAP1D in the mitochondria (3). MetAP activities are essential for survival in both bacteria and yeast (4-6). As a result, there has been a renewed interest in designing specific inhibitors against bacterial MetAP1 as novel antibiotics (7-10). We

and others have previously discovered that MetAP2 is the molecular target of fumagillin, a fungal metabolite and potent inhibitor of angiogenesis, validating MetAP2 as a novel target for anticancer treatment (*11, 12*). In fact, a semisynthetic analogue of fumagillin, TNP-470, has entered phase II clinical trials as an anticancer agent (*13*). TNP-470 preferentially inhibits endothelial cell growth in tumor vasculature by arresting the cell cycle in the late G1 phase (*14, 15*). Presumably, inhibition of MetAP2 by TNP-470 prevents the removal of methionine from one or more critical proteins and therefore their maturation. However, the identity of these MetAP2-specific substrates is currently unknown.

N-Terminal methionine removal is a cotranslational process and occurs as soon as a polypeptide emerges from the ribosome (16). Previous studies indicate that the fate of the N-terminal methionine is dictated by the substrate specificities of MetAPs, which require Met as the P1 residue and amino acids with small side chains as the P1' residue (e.g., Ala, Gly, Pro, Ser, Thr, or Val) (17-24). Amino acid residues at positions P2' and beyond also play a role. For example, a hemoglobin variant with a proline at position 3(P2') retains the initiator methionine in vivo, whereas mutation of the proline to Arg or Gln leads to complete cleavage of the methionine (20). Chang et al. (21) reported a 2-fold difference in the activity of purified yeast MetAP1 toward Met-Ala-Ile-Pro-Glu versus Met-Ala-Ile-Pro-Ser, which differ only at the P4' position. These studies clearly demonstrate the existence of sequence specificity by MetAPs. However, because these studies employed the individual synthesis and activity assay of each peptide, the sequences that have been tested represent only a small fraction of the possible protein N-terminal sequence space and are generally limited to the examination of the specificity at the P1, P1', and occasionally P2' positions. One recent study by Frottin et al. has generated a more complete specificity profile of E. coli MetAP1 and Pyrococcus furiosus MetAP2, via the synthesis and

[†]This work was supported by grants from the National Institutes of Health (NIH) (GM062820, CA132855, and CA078743). B.A.N. was supported by NIH Medical Scientist Training Program Grant T32GM07309.

^{*}To whom correspondence should be addressed: Department of Chemistry, The Ohio State University, 100 W. 18th Ave., Columbus, OH 43210. Telephone: (614) 688-4068. Fax: (614) 292-1532. E-mail: pei.3@osu.edu. Abbreviations: Abu (U), 2-aminobutyrate; Dabcyl- β -Ala-OSu, *N*-hydro-

¹Åbbreviations: Abu (U), 2-aminobutyrate; Dabcyl-β-Ala-OSu, N-hydroxylsuccinimidyl 3-{4-[4-(dimethylamino)benzoylamino}propionate; Dabcyl-OSu, N-{4-[4'-(dimethylamino)phenylazo]benzoyloxy}succinimide; Dde, N-1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl; EDC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; Fmoc-OSu, N-(9-fluorenylmethoxycarbonyloxy)succinimide; HBTU, O-benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate; HOBt, 1-hydroxybenzotriazole hydrate; MetAP, methionine aminopeptidase; Nle (M), norleucine; OBOC, onebead-one-compound; PCR, polymerase chain reaction; PED-MS, partial Edman degradation mass spectrometry; PEGA, amino polyethylene glycol; PGM1, phosphoglucomutase; PITC, phenyl isothiocyanate; TXNL1, thioredoxin-like protein 1.

Article

assay of ~120 short peptides (25). To the best of our knowledge, no systematic study has been performed for any eukaryotic MetAPs. A potential approach to systematically determining the substrate specificity of a MetAP is to screen it against a combinatorial peptide library. This, however, has not been possible because of the technical difficulty in differentiating reaction products from unreacted substrates, which are both peptides with free N-termini. Herein, we report a novel peptide library screening strategy and its application to determine the sequence specificity of *E. coli* MetAP1 and human MetAP1 and MetAP2. The specificity information should be useful in designing specific MetAP2 inhibitors as anticancer agents and compounds specific for the bacterial MetAP1 as antibacterial agents.

MATERIALS AND METHODS

Materials and General Methods. ¹H and ¹³C NMR spectra were recorded on a Bruker 400 DPX spectrometer at 400 and 100 MHz, respectively. Fmoc-protected L-amino acids were purchased from Advanced ChemTech (Louisville, KY), Peptides International (Louisville, KY), or NovaBiochem (La Jolla, CA). O-Benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) and 1-hydroxybenzotriazole hydrate (HOBt) were from Peptides International. All solvents and other chemical reagents were obtained from Aldrich, Fisher Scientific (Pittsburgh, PA), or VWR (West Chester, PA) and were used without further purification unless noted otherwise. N-(9-Fluorenylmethoxycarbonyloxy)succinimide (Fmoc-OSu) was from Advanced ChemTech. Phenyl isothiocyanate (PITC) was purchased in 1 mL sealed ampules from Sigma-Aldrich, and a freshly opened ampule was used in each experiment. N-{4-[4'-(Dimethylamino)phenylazo]benzoyloxy}succinimide (Dabcyl-OSu) was from ABD Bioquest (Sunnyvale, CA). Amino polyethylene glycol (PEGA) resin $(0.4 \text{ mmol/g}, 150-300 \ \mu\text{m} \text{ in water})$ was from Peptides International. Clear amide resin (90 μ m, 0.49 mmol/g) was from Advanced ChemTech. α -Cyano-4-hydroxycinnamic acid (α -CCA) was purchased from Sigma and recrystallized prior to use. E. coli MetAP1 was purified from an E. coli strain overproducing the enzyme as previously described (26). Recombinant human MetAP1 and Met-AP2 were expressed and purified as previously described (11, 26). Anti-Flag, anti-PGM1, and anti-TXNL1 antibodies were purchased from Sigma or Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).

Synthesis of the MetAP Library. The peptide library was synthesized on 2.0 g of PEGA resin (0.4 mmol/g, $150-300 \,\mu$ m in water). All of the manipulations were performed at room temperature unless otherwise noted. Synthesis of the N-1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl (Dde) linker began with acylation of the resin-bound amine with glutaric anhydride (3.0 equiv) in 15 mL of CH₂Cl₂ containing diisopropylethylamine (1.1 equiv). After 3 h, the resin was washed with CH₂Cl₂ and the newly formed carboxylic acid was treated with 15 mL of CH₂Cl₂ containing 5,5-dimethylcyclohexanedione (4.0 equiv), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI, 2 equiv), and N,N-diaminopyridine (2 equiv) for 36 h. The excess reagents were removed by filtration, and the beads were washed with CH₂Cl₂ (50 mL) and DMF (50 mL). Next, the resin was incubated with 1,5-diaminopentane (20 equiv) in 15 mL of CH_2Cl_2 to furnish the Dde linker. Coupling of the first amino acid and the rest of peptide synthesis followed standard Fmoc/HBTU chemistry using 4 equiv of Fmoc amino acids. To construct the random region, the resin was split into the desired number of equal portions and each portion was

coupled twice with 4 equiv of a different Fmoc amino acid with HBTU, HOBt, and N-methylmorpholine (NMM) for 2 h at room temperature. To differentiate isobaric amino acids during MS analysis, 5% (mol/mol) CD₃CO₂D was added to the coupling reaction mixture of Leu, whereas 5% CH₃CD₂CO₂D was added to the coupling reaction mixture of norleucine (27). After the last random residue had been coupled, the resin was pooled into three sublibraries according to the identity of the last random residue. Sublibraries I and II contained Ser and Thr as the N-terminal residues, respectively, while sublibrary III contained an equimolar mixture of the other 16 L-α-amino acids excluding Ser and Thr. The three sublibraries were separately coupled with 4 equiv of Fmoc-Met-OH and deprotected by treatment with the modified reagent K (79:7.5:5:5:2.5:1 TFA/phenole/H₂O/thioanisole/ ethanedithiol/anisole). The resin-bound sublibraries were washed exhaustively with CH₂Cl₂ and DMF, suspended in DMF, and stored under an argon atmosphere at 4 °C.

N-Hydroxylsuccinimidyl 3-{4-[4-(Dimethylamino)phe $nylazo]benzoylamino\}propionate (Dabcyl-\beta-Ala-OSu).$ To a 100 mL dry flask were added Dabcyl-OSu (0.366 mg, 1 mmol), DMF (25 mL), triethylamine (0.42 mL, 3.0 mmol), and β -alanine (0.091 g, 1.02 mmol). The mixture was stirred at room temperature for 18 h. The solvent was removed under vacuum, and the solid residue was washed with H₂O and then dried via azeotrope with toluene to give 0.322 g (88% yield) of a crude product. The crude product (0.322 g, 0.946 mmol) was dissolved in DMF (15 mL), to which N-hydroxysuccinimide (0.163 g, 1.42 mmol) and EDCI (0.272 g, 1.42 mmol) had been added. The mixture was stirred overnight, and the solvent was removed under vacuum. The solid residue was dissolved in dichloromethane, washed with H₂O, dried over Na₂SO₄, and concentrated to give a red solid (0.372 g, 90% yield): ¹H NMR (250 MHz, CDCl₃) δ 7.96-7.86 (m, 6H), 6.77 (d, 2H, J=9.3 Hz), 3.92 (m, 2H), 3.11 (s, 6H), 3.00-2.95 (m, 2H), 2.89 (s, 4H); HRMS (ESI) calcd for C₂₂H₂₄N₅O₅ $(M^+ + H)$ 438.1772, found 438.1764.

4-[4-(Dimethylamino)phenylazo]benzoic Acid Hydrazide. To a solution of Dabcyl-OSu (0.366 g, 1 mmol) in DMF was added dropwise anhydrous NH₂NH₂ (31.4 μ L, 1.0 mmol) at room temperature. The mixture was stirred for 20 min. The solvent was removed under vacuum, and the solid residue was washed with H₂O and dried under vacuum to give 0.253 g (89.4%) of the product as a red solid: ¹H NMR (400 Hz, DMSO-*d*₆) δ 9.86 (s, 1H), 7.97–7.93 (m, 2H), 7.82–7.77 (m, 4H), 6.86–6.82 (m, 2H), 4.55 (brs, 2H), 3.08 (s, 6H); ¹³C NMR (100 Hz, DMSO-*d*₆) δ 165.3, 154.0, 152.9, 142.7, 133.6, 128.1, 125.1, 121.6, 111.6, 39.9; HRMS (ESI) calcd for C₁₅H₁₇N₅ONa (M⁺ + Na) 306.1331, found 306.1323.

MetAP Library Screening (method A). A typical screening involved 20 mg of sublibrary III (~71000 beads), which was transferred into a disposable Biospin column (2.0 mL). The resin was washed with DMF (5 × 1.8 mL), H₂O (5 × 1.8 mL), and a MetAP screening buffer [30 mM Hepes (pH 7.4), 150 mM NaCl, and 0.1 mM CoCl₂]. After incubation with the screening buffer for 10 min, the resin was treated with 75–500 nM MetAP at room temperature for 30–180 min. The reaction was terminated via removal of the enzyme solution (via filtration) and the resin washed with a 0.2 M EDTA solution (5 × 1.8 mL). After a 10 min incubation with 0.2 M EDTA, the resin was washed with 1 M NaCl (5 × 1.8 mL) and incubated with 1 M NaCl for 10 min. The resin was next washed with H₂O (5 × 1.8 mL) and DMF (5 × 1.8 mL) and treated with 1.2 equiv of a 39:1 (mol/mol) Fmoc-OSu/Dabcyl- β -Ala-OSu mixture dissolved in a 9:1 (v/v) DMF/phosphate buffer (50 mM, pH 8.0) for 1.5 h. The resulting resin was washed with DMF (5 \times 1.8 mL) and incubated with 20% piperidine in DMF for 5 and 15 min. The resin was washed with DMF (5 \times 1.8 mL) and H₂O (5 \times 1.8 mL) and incubated overnight with 100 mg/mL CNBr in 70% formic acid at room temperature. After the overnight incubation, the resin was thoroughly washed with 70% HCOOH and transferred into a 60 mm \times 15 mm Petri dish with H₂O. After the addition of a drop of 6 M HCl into the Petri dish, the red-colored beads were manually removed from the dish using a micropipet with the aid of a dissecting microscope. A control reaction without MetAP produced no colored beads.

MetAP Library Screening (method B). Sublibrary I or II (typically 4.3 mg) was washed and treated with MetAP as described above. After the MetAP reaction, the resin was washed exhaustively with H₂O and then treated with 2 equiv of NaIO₄ dissolved in 0.01 M sodium phosphate buffer (pH 7.0) for 5 min at room temperature. The reaction solution was removed, and the resin was washed with H₂O. The resin was suspended in 0.9 mL of 1% ethylene glycol in H₂O and incubated for 10 min. The resin was washed with H₂O (5 \times 0.9 mL) and treated with 0.1 equiv of Dabcyl-NHNH₂ in a 7:3 (v/v) mixture of 30 mM NaOAc buffer (30 mM, pH 4.5) and MeCN for 1.5 h at room temperature. The reaction solution was removed, and the resin was washed with MeCN (5×0.9 mL) and DMF (5×0.9 mL). The resin was treated with 10 equiv of NaBH₃CN in 0.9 mL of DMF containing 1% HOAc for 36 h. After that, the resin was washed with DMF (5 \times 0.9 mL) and H₂O (5 \times 0.9 mL) and transferred into a Petri dish with H₂O. The solution was acidified with HCl, and the red-colored beads were manually removed from the library.

Peptide Sequencing by Partial Edman Degradation Mass Spectrometry (PED-MS). Positive beads derived from the same screening experiment were pooled into a single reaction vessel, suspended in 160 μ L of a 2:1 (v/v) pyridine/water mixture containing 0.1% triethylamine, and mixed with an equal volume of an 80:1 (mol/mol) PITC/Fmoc-OSu mixture in pyridine (625 mM PITC and 7.8 mM Fmoc-OSu). The reaction was allowed to proceed for 6 min at room temperature, and the beads were washed sequentially with pyridine, CH_2Cl_2 , and TFA. The beads were treated twice with 500 μ L of TFA for 6 min each. The beads were washed with CH₂Cl₂ and pyridine, and the PED cycle was repeated five (for hits from method A) or six times (for hits from method B). Finally, the beads were treated twice with 1 mL of 20% piperidine in DMF at room temperature (5 min each). The beads were washed exhaustively with water and transferred into individual microcentrifuge tubes (one bead/tube). Each bead was treated with $10 \,\mu$ L of 1.5% hydrazine in a THF/H₂O mixture (1:1) at room temperature for 15 min. The solution was acidified by the addition of 10 μ L of 7% TFA in H₂O. The solvent was removed under vacuum, and the released sample was dissolved in $5 \,\mu\text{L}$ of 0.1% TFA in water. One microliter of the peptide solution was mixed with $2 \mu L$ of saturated α -cyano-4-hydroxycinnamic acid in acetonitrile and 0.1% TFA (1:1), and 1 μ L of the resulting mixture was spotted onto a 384-well sample plate. Mass spectrometry was performed at the Campus Chemical Instrument Center of The Ohio State University on a Bruker III MALDI-TOF instrument in an automated manner. The data obtained were analyzed by Moverz software (Proteometrics LLC, Winnipeg, MB).

Synthesis of Individual Peptides. Individual peptides were synthesized using standard solid-phase Fmoc/HBTU chemistry. Each peptide was synthesized on 100 mg of CLEAR-amide resin (0.49 mmol/g). The ninhydrin test was used to monitor the completion after each coupling reaction. After cleavage and

deprotection with a modified reagent K (7.5% phenol, 5% water, 5% thioanisole, 2.5% ethanedithiol, and 1% anisole in TFA), the crude peptides were precipitated in cold diethyl ether and purified by reversed-phase HPLC on a C₁₈ column (Varian, 120 Å, 100 mm × 250 mm). The identity of the peptides was confirmed by MALDI-TOF mass spectrometric analyses.

MetAP Activity Assay. A typical assay reaction mixture (total volume of 100 μ L) contained 1× MetAP reaction buffer [30 mM Hepes (pH 7.4), 150 mM NaCl, and 0.1 mM CoCl₂] and $0-200 \ \mu M$ peptide substrate. The reaction was initiated by the addition of MetAP (final concentration of 5-1000 nM) and quenched after 10-90 min with the addition of three drops of TFA. The reaction mixture was centrifuged at 15000 rpm in a microcentrifuge for 5 min, and the clear supernatant was analyzed by reversed-phase HPLC on an analytical C18 column (Vydac C18, 300 Å) eluted with a linear gradient of acetonitrile in water containing 0.05% TFA (from 10 to 40% acetonitrile over 18 min). The percentage of substrate-to-product conversion was determined from the peak areas of the remaining substrate and the reaction product (monitored at 214 nm) and kept at < 20%. The initial rates were calculated from the conversion percentages and plotted versus [S]. Data fitting against the Michaelis–Menten equation $V = V_{\text{max}}[S]/$ $(K_{\rm M} + [S])$ or the simplified equation $V = k_{\rm cat}[E][S]/K_{\rm M}$ (when $K_{\rm M} \gg$ [S]) gave the kinetic constants $k_{\rm cat}$, $K_{\rm M}$, and/or $k_{\rm cat}/K_{\rm M}$.

DNA Constructs and Cell Transfection. The coding sequences of BTF3L4, phosphoglucomutase (PGM1), and thioredoxin-like protein 1 (TXNL1) proteins were amplified by the polymerase chain reaction (PCR) from the cDNA pool of HE-K293T cells with the introduction of EcoRI and BamHI restriction sites. The DNA primers used for PCR amplification of the BTF3L4 gene were 5'-CGCGAATTCAGCATGAATCAAGAAAAGT-TAGCC-3' and 5'-CCGGGATCCGTTAGCTTCATTCTTTG-ATGC-3'. The primers used for the PGM1 gene were 5'-CGCG-AATTCGCGATGGTGAAGATCGTGACAGTTAAG-3' and 5'-CGCGGATCCGGTGATGACAGTGGGTGC-3'. The primers used for the TXNL1 gene were 5'-GAGCGGCCGCCATGGT-GGGGGTGAAG-3' and 5'-CGCGCGGATCCGTGGCTTTC-TCCTTTTTTGC-3'. The PCR products were cloned into the p3xFLAG-CMV-14 vector (Sigma), resulting in the addition of a C-terminal 3xFlag tag. The final constructs were verified by DNA sequencing. The plasmids for transfection were isolated from E. coli using the PureLink HiPure Plasmid Filter Purification Kit and PureLink HiPure Precipitator Module (Invitrogen).

HEK 293T cells were grown in a humidified environment at 37 °C with 5% CO₂ in low-glucose DMEM (Gibco) supplemented with 10% FBS (Gibco) and 1% penicillin/streptomycin (Gibco) unless otherwise stated. One day prior to transfection, the cells were seeded at a density of 2×10^6 cells per 10 cm Petri dish containing 10 mL of medium. Immediately before transfection, 10 μ g of the appropriate plasmid DNA (p3xFLAG-CMV-14-BTF3L4, p3xFLAG-CMV-14-PGM1, or p3xFLAG-CMV-14-TXNL1) was added to 1 mL of serum-free DMEM, to which 25 μ L of Superfect transfection reagent (Qiagen, 301305) was added. The mixture was incubated at room temperature for 10 min. The cell medium was then changed, and the transfection mixture was added in a dropwise fashion.

Initiator Methionine Release Assay. This assay was a modification of a previously described procedure (28, 29). At 19.5 h post-transfection, the cells were treated for 4.5 h with either vehicle (DMSO), MetAP1 inhibitor IV-43 (30) (10 μ M), MetAP2 inhibitor TNP-470 (100 nM), or both in 4 mL of methionine-free DMEM supplemented with 4.5 g/L glucose and sodium pyruvate

Scheme 1: Synthesis of the MetAP Substrate Library



^aReagents and conditions: (a) glutaric anhydride (3 equiv), DIPEA, CH₂Cl₂; (b) 5,5-dimethylcyclohexane-1,3-dione (4 equiv), EDC (2 equiv), DMAP (2 equiv), CH₂Cl₂; (c) NH₂(CH₂)₅NH₂ (20 equiv), CH₂Cl₂; (d) solid-phase peptide synthesis using Fmoc chemistry, split-and-pool synthesis at random positions, and deprotection; (e) 1.5% NH₂NH₂ in a 1:1 THF/H₂O mixture.

(Mediatech) and 10% dialyzed FBS (Gibco). For treatment for the final 4 h, the cells were incubated with 0.2 mCi of [³⁵S]methionine (PerkinElmer, NEG709A). The medium was removed by aspiration, and the cells were resuspended in 5 mL of ice-cold PBS, collected by centrifugation at 225g, and resuspended using a Pasteur pipet in 1 mL of ice-cold RIPA buffer [50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS (pH 8.0)] containing $1 \times$ protease inhibitor cocktail (Roche, 11872580001). Following a 10 min incubation (at 4 °C), the cell lysate was centrifuged at ~16000g for 20 min (4 °C), and the cleared supernatant was transferred to a fresh tube containing 30 µL of anti-Flagconjugated agarose resin (Sigma, A2220) that had been equilibrated by being washed with RIPA buffer $(3 \times 1 \text{ mL})$. After incubation for 1.5 h on a rotating wheel (4 °C), the resin was collected by centrifugation at 500g for 30 s (4 °C) and washed five times with 0.9 mL of ice-cold RIPA buffer (by inverting the tube 15 times between centrifugation steps). Finally, the resin was washed twice with 0.9 mL of ice-cold MetAP reaction buffer [50 mM Hepes, 150 mM NaCl, and 100 μ M CoCl₂ (pH 7.5)] before being resuspended in 250 μ L of MetAP reaction buffer and split into two equal aliquots. Each aliquot was centrifuged at 500g, and the supernatant was aspirated. The supernatant from one aliquot was discarded (the "no enzyme" tube), and 50 μ L of MetAP reaction buffer was added to the resin. The supernatant from the other aliquot (the "enzyme reaction tube") was set aside as the "wash" sample, and recombinant MetAP1 and MetAP2 (5 µM each) were added to the resin suspended in 50 μ L of MetAP reaction buffer. After incubation overnight (~16 h) at room temperature, 75 μ L of MetAP reaction buffer was added to each tube; then the resin was pelleted, and the supernatant was transferred to a fresh tube. The ${}^{35}\overline{S}$ content of each sample (including the wash sample) was determined when each sample was mixed with 1 mL of scintillation fluid (PerkinElmer, 1200-439) and scintillation counting on a 1450 MicroBeta apparatus (Wallac). The percentage of [³⁵S]methionine release was calculated from the ratio of counts in the reaction buffer to the sum of these counts and the counts from the corresponding resin sample.

RESULTS AND DISCUSSION

Design and Synthesis of the MetAP Substrate Library. A one-bead-one-compound (OBOC) MetAP substrate library in

the form of NH2-MX1X2X3X4X5LNBBR-Dde-resin [where B is β -alanine and $X^1 - X^5$ are 2-aminobutyrate (Abu or U) and norleucine (Nle or M), which were used as Cys and Met surrogates, respectively, or any of 16 proteinogenic amino acids except for Arg, Cys, Lys, and Met] was synthesized on PEGA resin (0.4 mmol/g, $150-300 \ \mu m$ in diameter when swollen in water) (Scheme 1). A methionine was placed at the N-termini of all sequences because it is already well established that all MetAPs have a stringent requirement for Met as the P1 residue (21, 31). Arg, Lys, Cys, and Met were excluded (or replaced) from the random region because they would interfere with the screening procedure (vide infra). The invariant sequence LNBBR was added to facilitate MALDI MS analysis, by providing a fixed positive charge (Arg) and shifting the mass of all peptides to > 500 (to avoid overlap with MALDI matrix signals). The peptides were covalently linked to the PEGA resin via a Dde linker, which permits facile peptide release by treatment with hydrazine prior to MS analysis. To construct the Dde linker, the free amino group on PEGA resin was first acylated with glutaric anhydride, and the resulting carboxylic acid (1) was activated with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and condensed with 5,5-dimethylcyclohexane-1,3-dione to give enol 2 (32). Subsequent reaction of enol 2 with excess 1,5diaminopentane provided the desired Dde linker 3 containing a free amine as the anchor for peptide synthesis. After the addition of the LNBBR sequence using standard Fmoc/HBTU chemistry, the random region was synthesized via the split-and-pool method (33, 34). After the addition of the last random residue (X^{1}) , the library was split into three sublibraries. Sublibraries I and II contained Ser and Thr as the X^1 residue, respectively, whereas in sublibrary III, the X¹ residue represented an equimolar mixture of the other 16 amino acids. The theoretical diversity of the library is 18^5 or 1.9×10^6 .

MetAP Library Screening. Two different methods were devised to screen the MetAP substrate library. Method A (Scheme 2a) was designed for sublibrary III, which was subjected to limited MetAP reaction, so that only those beads that carried the most efficient substrates of MetAP would undergo partial cleavage of the N-terminal methionine (usually a few percent), while the vast majority of beads (which displayed poorer substrates or inactive peptides) would have little or no reaction. The library was then



treated with a 39:1 (mol/mol) mixture of Fmoc-OSu and Dabcyl- β -Ala-OSu, a red dye molecule. This resulted in the N-terminal acylation (or carbamovlation) of all library peptides (both MetAP reaction products and unreacted substrates), and all of the library beads became red (due to attachment of the Dabcyl moiety). Next, the library was treated with piperidine to remove the N-terminal Fmoc group, followed by CNBr to cleave any N-terminal methionine. For beads with peptides that did not undergo any MetAP reaction, CNBr would remove the N-terminal methionine, along with the Dabcyl group, rendering these beads colorless. On the other hand, any MetAP reaction products would not be affected by the CNBr treatment because they no longer contained any methionine in their sequences. Thus, those beads that had undergone significant MetAP reaction (positive beads) would retain the Dabcyl group and remain red. The positive beads were manually removed from the library using a micropipet, and their peptide sequences were determined by PED-MS (27). It is worth noting that the use of a 39:1 Fmoc-OSu/Dabcyl-β-Ala-OSu mixture was critical for successful library screening, as it ensured that there were sufficient amounts of peptides with free N-termini (after Fmoc removal) for PED-MS analysis. It also improved the color contrast between positive and negative beads. When only Dabcyl- β -Ala-OSu was used for N-terminal acylation, all of the library beads retained significant red color after the CNBr treatment, because methionine removal by CNBr was not quantitative.

The method described above was less effective for sublibraries I and II (which contained Ser and Thr at the Pl' position, respectively) because CNBr cleavage of methionine is inefficient when Ser or Thr is next to methionine (35). The β -hydroxyl group of Ser (or Thr) can intramolecularly react with the five-membered ring intermediate, resulting in the conversion of the methionine into a homoserine instead of peptide bond cleavage. We therefore developed an alternative approach (method B) for those two sublibraries (Scheme 2b). Enzymatic cleavage of the N-terminal methionine from the library peptides generated an N-terminal Ser or Thr, which was selectively oxidized by sodium periodate into a glyoxyl

group. The newly formed aldehyde group was then selectively conjugated with Dabcyl-hydrazide and reduced with NaBH₃CN. Again, the resulting positive (red-colored) beads were readily identified from the library and sequenced via PED-MS.

Substrate Specificity of E. coli MetAP1. A total of 105 mg of sublibrary III ($\sim 3.9 \times 10^5$ beads) was screened against E. coli MetAP1 in five separate experiments (25 mg of resin each). The most colored beads were isolated and sequenced by PED-MS to give 236 complete sequences, which should represent the most efficient substrates of E. coli MetAP1 (Table 1). Similar sequences were selected from each screening experiment, demonstrating the reproducibility of the screening method. E. coli MetAP1 has the most stringent specificity at the P1' position, with Ala being the most preferred amino acid (in 84% of all selected sequences), followed by glycine (10%) and 2-aminobutyrate (6%) (Figure 1a). At the P2' position, E. coli MetAP1 tolerates a wide variety of amino acids, but with preference for hydrophilic residues (Glu, Asp, Asn, Gln, Ser, and Thr) or small residues such as Ala and Abu. A few of the selected peptides also contained a Phe at the P2' position. Interestingly, of the 236 selected peptides, none contained a proline, histidine, or tryptophan at this position. The enzyme also has broad specificity at the P3' position, where hydrophobic residues were frequently selected, whereas acidic residues (especially Asp), Gly, His, and Trp were underrepresented. There appears to be a negative correlation between the P2' and P3' positions with respect to acidic amino acids. When the P2' residue was acidic, the P3' residue was almost always hydrophobic, and vice versa, when Asp or Glu was present at the P3' position, the P2' residue was typically hydrophobic (Table 1). None of the most preferred substrates contained acidic residues at both P2' and P3' positions. No obvious selectivity was observed at the P4' or P5' position. Screening of sublibraries I and II (9 mg each) by method B revealed a similar specificity profile at the P3'-P5' positions, although Ala and acidic residues (Asp and Glu) were more frequently selected at the P2' position when Ser or Thr was the P1' residue (Figure 1b and Table S1 of the Supporting Information).

Table 1: Most Preferred Substrates of *E. coli* MetAP1 Selected from Sublibrary III (236 total)^{*a*}

| AAADV | AEUEI | ANVIN | AUPSE |
|-----------|-------|-------|-------|
| AADEI | AEUEG | ANVHI | AUSFG |
| AAELI | AEVMH | ANVIG | AUTAN |
| AAFNT | AEVMA | ANYGA | AUTNP |
| AAFTQ | AEVMD | ANYQG | AUUNH |
| AAIST | AEVNI | AQAGE | AUUFG |
| AALHQ | AEVTE | AQFAG | AUUEF |
| AAMEP | AEVIS | AQFGP | AUVHT |
| AANDI | AEVDI | AQGUI | AVEGY |
| AANN I | AEYPV | AQLVG | AVGFP |
| AAPEI | AEYGA | AQNVU | AVNHI |
| AATSI | AFAEG | AQNIP | AVTHT |
| AATYP | AFDND | AQNFT | AVTEU |
| AATNT | AFEGP | AQNFP | AVUAD |
| AAUIS | AFNUG | AQQUH | AVUDS |
| AAUHI | AFNQS | AQQUD | AYNQQ |
| AAUMD | AFPGI | AQSAN | AYNNU |
| AAASU | AFPNT | AQSMI | AYSET |
| ADAAL | AFPSP | AQSMI | AYSSG |
| ADAFE | AFSHS | AQSVQ | AYVSL |
| ADFEU | AFSTH | AQSNI | GAEIE |
| ADLMP | AFSDI | AQSTY | GAMHE |
| ADMDI | AFSNS | AQSSA | GAUEY |
| ADPEM | AFSQT | AQSHU | GDFDF |
| ADSLG | AFTMP | AQTEM | GDMLP |
| ADSAF | AFVGP | AQTAS | GDVSL |
| ADTQF | AGGPD | AQVUT | GEUID |
| ADTIN | AIDED | AQVGI | GFADQ |
| ADTAI | ALAGE | ASAES | GFAGE |
| ADUGA | ALUVU | ASFUU | GFIDN |
| ADUAA | AMAEQ | ASINE | GFSEI |
| ADWDM | AMANI | ASLEV | GFSQE |
| ADYNI | AMEVD | ASLNS | GFSSQ |
| AEAFD | AMNSG | ASMHQ | GLAHG |
| AEANY | AMUAP | ASNVG | GLTDT |
| AEFEM | ANADF | ASNIT | GMNEP |
| AEFHE | ANAEQ | ASSMN | GMUEE |
| AEISI | ANAEH | ASTHE | GMUTE |
| AEIED | ANFUT | ASUTL | GNFEE |
| $AEIEI^b$ | ANISI | ASVSM | GNLME |
| AEIIG | ANIDE | ASVHV | GSLES |
| AELID | ANLNV | ASVVS | GSTLE |
| AELFA | ANLEQ | ASYSU | GSUEF |
| AELEE | ANMIG | ATFTE | GUEEF |
| AELVU | ANMTA | ATIEE | UDYGD |
| AEMEI | ANMDF | ATMNS | UEFEE |
| AEMSN | ANNHE | ATQPI | UEMFE |
| AEMNQ | ANSQY | ATUYT | UETIN |
| AEMEW | ANTQL | ATVAU | UFSEV |
| AENYP | ANTVG | AUADF | UFUET |
| AEPIV | ANTEA | AUEYD | UNQIH |
| AESTF | ANTYT | AUFGA | UNVHN |
| AETLH | ANTVA | AUGEF | UNVDM |
| AETTY | ANUSI | AUIPS | UQGEF |
| AETID | ANUID | AUIGP | UQUNG |
| AEUVG | ANUEM | AUIAP | USMED |
| AEUGG | ANUQY | AUPAI | USUIT |
| AEUEH | ANVED | AUPSN | UTDLE |
| AEUOF | ANVIY | AUPSE | UUEID |

^{*a*}Sequences were obtained from five screening experiments performed at 75–100 nM *E. coli* MetAP1. U, α -L-aminobutyric acid; M, norleucine. ^{*b*}Peptide selected for further kinetic analysis.

To identify the less efficient substrates and MetAP-resistant sequences, sublibrary III (40 mg) was treated exhaustively with a high concentration of *E. coli* MetAP1 (1.0 μ M) for an extended period of time (overnight). In addition to intensely colored beads, this screening experiment also produced many medium-colored



FIGURE 1: Substrate specificity of *E. coli* MetAP1. (a) Most preferred substrates selected from sublibrary III (total of 236 sequences). (b) Most preferred substrates from sublibraries I and II (total of 124 sequences). (c) Val-containing sequences (at position P1') derived from medium-colored beads in sublibrary III (total of 92 sequences). (d) Ala-, Abu-, and Gly-containing sequences (at position P1') derived from medium-colored beads in sublibrary III (total of 140 sequences). (e) Sequences derived from colorless beads in sublibrary III (total of 140 sequences). (e) Sequences. Displayed are the amino acids identified at each position (P1'-P5'). Occurrence on the *y*-axis represents the number of selected sequences that contained a particular amino acid at a certain position.

and lightly colored beads ($\sim 15\%$ of all library beads), which should represent the less efficient substrates of *E. coli* MetAP1. We randomly selected some of the medium-colored beads for sequence analysis and obtained 232 complete sequences (Table S2 of the Supporting Information). Our results showed that 40% of these less efficient substrates contained a Val as the P1' residue, while the rest of peptides had Gly (27%), Abu (23%), and Ala (10%) at this position. When the subset of sequences that contained Val as the P1' residue was analyzed, the specificity profile at the P2'-P5' positions was essentially identical to that observed for the most efficient substrates (Figure 1c). Similar analysis of the other subset of sequences (which contained Gly, Abu, or Ala as the P1' residue) showed that they usually contained less favorable amino acids at the P2' (e.g., Gly, Ile, Leu, and Pro) and/or P3' positions (e.g., Asp, Glu, and His) (Figure 1d). Sequence analysis of 171 randomly selected colorless beads from the library showed that most of the MetAP-resistant peptides contained amino acids with large side chains like the P1' residue, while none of them had Ala at the P1' position (Figure 1e and Table S3 of the Supporting Information). Only six of the peptides contained Gly (MGDVFQ and MGPTET), Abu (MUHINS, MUPETF, and MUILVE), or Val (MVLFHH) at the P1' position. These peptides either contained a disfavored residue at the P2' position (Pro or His) or were very hydrophobic (MUILVE and MVLFHH), making the beads poorly swelled in aqueous solution and thus poorly accessible to the enzyme during library screening. As expected from the large number of colorless beads (~75% of all beads), there was no obvious "selectivity" at the P2'-P5' positions. These data indicate that all N-methionyl peptides containing a small P1' residue (Ala, Gly, Abu, Ser, Thr, and Val) are accepted as E. coli MetAP1 substrates, albeit with different catalytic efficiencies.

Substrate Specificity of Human MetAP1. Human MetAP1 was similarly screened against sublibraries I–III to identify peptide sequences that are most preferred or less preferred by the enzyme, and resistant to the enzyme. The most intensely colored beads were selected from sublibraries III (60 mg) and I (9 mg) and sequenced to give 128 and 74 unambiguous sequences, respectively (Tables S4 and S5 of the Supporting Information). Similar sequences were selected from the two sublibraries (Figure 2a,b). In general, human MetAP1 has a specificity profile similar to that of E. coli MetAP1 but also has some unique features. Like the E. coli enzyme, human MetAP1 prefers Ala at the P1' position, but this preference is stronger than that of E. coli MetAP1 (124 of the 128 best substrates had Ala as the P1' residue). Only four peptides contained Gly (three peptides) or Abu (one peptide) as the P1' residue. The underrepresentation of Abu at this position suggests that amino acids with larger (than a methyl group) side chains are poorly tolerated by the human MetAP1 active site. This notion is further supported by the data from sublibrary II (which contained Thr as the P1' residue) (Figure 2c and Table S6 of the Supporting Information). Screening of sublibrary II against human MetAP1 produced only lightly colored beads, despite the use of a higher enzyme concentration (800 nM) and a longer reaction time (2 h), suggesting that any peptide containing a Thr at the P1' position is a relatively poor substrate of human MetAP1. Other features shared with the *E. coli* enzyme include the absence (or underrepresentation) of Pro at the P2' position and His and Trp at both P2' and P3' positions among the most active substrates. The most striking difference between the E. coli and human MetAP1 enzymes lies in their different tolerance to acidic residues. While E. coli MetAP1 prefers Asp and Glu at P2', P4', and P5' positions (Figure 1), the human enzyme strongly disfavors acidic residues at all positions. Of the 245 most preferred substrates selected from sublibraries I-III, only one sequence [MA(Nle)DWE] contained acidic residues. Another difference is that while E. coli MetAP1 disfavors Gly at positions P2' and P3', the human enzyme has no such discrimination.



FIGURE 2: Substrate specificity of human MetAP1. (a) Most preferred substrates selected from sublibrary III (total of 128 sequences). (b) Most preferred substrates from sublibrary I (total of 74 sequences). (c) Most preferred substrates selected from sublibrary II (total of 43 sequences). (d) Ala-, Abu-, and Gly-containing sequences (at position Pl') derived from medium-colored beads in sublibrary III (total of 50 sequences). (e) Val-containing sequences (at position Pl') derived from medium-colored beads in sublibrary III (total of 50 sequences). (e) val-containing sequences (at position Pl') derived from medium-colored beads in sublibrary III (total of 24 sequences). Displayed are the amino acids identified at each position (Pl'-P5'). Occurrence on the *y*-axis represents the number of selected sequences that contained a particular amino acid at a certain position.

The less optimal substrates and inactive peptides were identified by treating sublibrary III (12 mg) with a high concentration of human MetAP1 (2.7 μ M) for 24 h and randomly selecting a fraction of the medium-colored and colorless beads for sequence analysis. The less optimal substrates contained Val (33%), Gly (28%),

Article

Abu (24%), and Ala (15%) as the P1' residue (Table S7 of the Supporting Information). Of the 48 Gly-, Abu-, and Ala-containing (at position P1') peptides, 35 contained at least one acidic residue, often at the P2' and/or P3' position, while three other peptides had Pro as the P2' residue (Figure 2d). The Val-containing peptides (at position P1') contained no Pro at the P2' position and many fewer acidic residues in their sequences (Figure 2e). None of the MetAP1-resistant peptides contained Ala or Glv at the P1' position, while two peptides had Abu or Val as the P1' residue (Figure S1 of the Supporting Information). These data provide further support for our conclusion that a larger P1' residue (e.g., Val and Thr), a Pro at the P2' position, and/or acidic residues at positions P2'-P5' can decrease the catalytic activity toward human MetAP1. They also suggest that human MetAP1, like the E. coli enzyme, will accept essentially all N-methionyl peptides containing Ala, Gly, Abu, Ser, Thr, or Val at the P1' position as substrates, although the Thr- and Val-containing peptides are generally inefficient substrates.

Substrate Specificity of Human MetAP2. Sublibraries I (4.3 mg), II (4.3 mg), and III (80 mg) were screened against human MetAP2, and the most intensely colored beads were sequenced to give 96, 65, and 632 complete sequences, respectively (Tables S8-S10 of the Supporting Information). In addition, 88 medium-colored beads were isolated from sublibrary III and sequenced (Table S11 of the Supporting Information). In general, human MetAP2 has a specificity profile very similar to that of human MetAP1 (Figure 3). For example, both human MetAP1 and MetAP2 disfavor Pro at position P2', Trp at positions P2' and P3', and acidic residues at positions P2'-P5'. The main difference between the two enzymes is their specificity at the P1' position. While only one of the 128 most preferred substrates of human MetAP1 contained an Abu as the P1' residue, MetAP2 selected Abu with the second highest frequency (122 of 632 sequences), more frequently than Gly (90 sequences). Moreover, 19 of the most preferred substrates had a Val as the P1' residue. This suggests that the S1' site of human MetAP2 is more capable of accommodating amino acids with larger side chains than MetAP1 does. This notion is also supported by our data on sublibrary II. We found that treatment of sublibrary II with 250 nM human MetAP2 generated intensely colored beads in 2 h, while treatment with 800 nM human MetAP1 for 2 h produced only lightly colored beads. We noted that unlike E. coli and human MetAP1, MetAP2 selected a significant number of His residues at positions P2' and P3'. The underlying reason is not yet clear.

Kinetic Properties of Selected MetAP Substrates. Fifteen peptides were synthesized individually on a larger scale, purified by HPLC, and assayed against the three MetAPs to confirm the screening results as well as provide specificity data on amino acid residues excluded from the library (i.e., Arg and Lys) (Table 2, entries 1-15). Peptides 1 and 2 are two of the most preferred substrates of E. coli MetAP1, selected from sublibraries III and I, respectively (Table 1 and Table S1 of the Supporting Information). Peptide 12 is a preferred substrate of human MetAP2 selected from sublibrary III (Table S8 of the Supporting Information). The rest of the peptides are variants of peptides 1 and 12, designed to test the effect of the P1'-P3' residues on MetAP activity. A Tyr was added to the C-terminus of each peptide to facilitate their concentration determination. Since most of the peptides did not reach saturation at the highest concentration tested (1.0 mM), only their $k_{\text{cat}}/K_{\text{M}}$ values are used for comparison.

As expected, peptides 1 and 2 were highly active toward the *E*. *coli* enzyme, having k_{cat}/K_{M} values of 14000 and 28000 M⁻¹ s⁻¹,



FIGURE 3: Substrate specificity of human MetAP2. (a) Most preferred substrates selected from sublibrary III (total of 632 sequences). (b) Most preferred substrates from sublibraries I and II (total of 144 sequences). (c) Ala-, Abu-, and Gly-containing sequences (at position P1') derived from medium-colored beads in sublibrary III (total of 52 sequences). (d) Val-containing sequences (at position P1') derived from medium-colored beads in sublibrary III (total of 16 sequences). Displayed are the amino acids identified at each position (P1'-P5'). Occurrence on the y-axis represents the number of selected sequences that contained a particular amino acid at a certain position.

respectively (Table 2). Replacement of the Ala at the P1' position with Gly, Pro, Thr, and Val decreased the activity by 3.4-, 4.7-, 9.3-, and 44-fold, respectively. This is largely consistent with the screening results, except for the results for the proline-containing peptide. Previous studies have also shown that peptides containing Pro as the P1' residue are efficiently hydrolyzed by MetAPs (17-25). Thus, the absence of Pro from the P1' position among the selected substrates was likely caused by the bias of the screening procedure (method A). Proline, which bears a secondary amine, is significantly less reactive with respect to activated esters such as Dabcyl- β -Ala-OSu than the other 19 proteinogenic amino acids (36). Presumably, MetAP reaction products that contained an N-terminal proline were not efficiently labeled with Dabcyl- β -Ala-OSu and became false negatives. Replacement of

|--|

| | $k_{\rm cat}/K_{\rm M}~({\rm M}^{-1}~{\rm s}^{-1})$ | | | | | |
|-------------------------------|-----------------------------------------------------|-------------------|------------------|----------------------|-------|--|
| relative activity of MetAP2/1 | human MetAP2 | human MetAP1 | E. coli MetAP1 | peptide | entry | |
| 0.63 | 1040 ± 50 | 1700 ± 160 | 14000 ± 3900 | $MAEIEIY^b$ | 1 | |
| ND | ND | ND | 28000 ± 1100 | $MSDFIGY^b$ | 2 | |
| 3.6 | 660 ± 20 | 180 ± 8 | 4100 ± 120 | MGEIEIY | 3 | |
| 0.88 | 140 ± 60 | 160 ± 8 | 3000 ± 1490 | MPEIEIY | 4 | |
| 16 | 460 ± 60 | 29 ± 2 | 1500 ± 50 | MTEIEIY | 5 | |
| >200 | 450 ± 180 | NA | 380 ± 110 | MVEIEIY | 6 | |
| 3.5 | 23300 ± 1700 | 6600 ± 600 | 18900 ± 1300 | MARIEIY | 7 | |
| ND | ND | ND | 13500 ± 7600 | MAGIEIY | 8 | |
| 0.43 | 540 ± 25 | 1300 ± 20 | NA | MAPIEIY | 9 | |
| 1.4 | 5000 ± 3800 | 3580 ± 350 | 14500 ± 550 | MAHIEIY | 10 | |
| 116 | 860 ± 210 | \sim 7 | ND | MVKIEIY | 11 | |
| 0.88 | 36000 ± 1900 | 41000 ± 18000 | ND | $MAHAIHY^b$ | 12 | |
| 3.7 | 37000 ± 6200 | 10000 ± 340 | ND | MAGAIHY | 13 | |
| 0.51 | 4900 ± 750 | 9600 ± 350 | ND | MAWIEIY | 14 | |
| 0.41 | 2160 ± 800 | 5300 ± 90 | ND | MAEWEIY | 15 | |
| 63 | 4000 ± 240 | 64 ± 5 | ND | MVHQVLY ^c | 16 | |
| 200 | 2600 ± 60 | 13 ± 2 | ND | MVNPTVY ^c | 17 | |
| 175 | 2600 ± 1000 | 15 ± 1 | ND | MVLSPAY ^c | 18 | |
| 74 | 2070 ± 280 | 28 ± 1 | ND | MVGVKPY ^c | 19 | |
| 79 | 10000 ± 1000 | 130 ± 6 | ND | MVAAAAY ^c | 20 | |

^{*a*}All peptides contained a free N-terminus and a C-terminal amide. NA, no detectable activity; ND, not determined. ^{*b*}Peptides selected from the combinatorial library. ^{*c*}Peptides derived from human proteins.

the P2' residue (Glu) with an arginine, which was excluded from the library for technical reasons, slightly increased the catalytic activity (by 1.3-fold). This suggests that the frequent selection of acidic residues at the P2' position was not due to the presence of favorable charge–charge interactions; the *E. coli* enzyme simply prefers a hydrophilic residue at this position. Indeed, other neutral, hydrophilic residues such as Asn, Gln, and Ser were also frequently selected at this position (Figure 1). Consistent with the absence of Pro from the P2' position among the most preferred substrates, peptide 9 (MAPIEIY) had an activity that was too low to be reliably determined by the HPLC assay. A surprising finding was that peptide 10, which contains a His at the P2' position, had excellent activity $(k_{\text{cat}}/K_{\text{M}} = 14500 \text{ M}^{-1} \text{ s}^{-1})$, even though His was not at all selected at this position (Figure 1). Careful kinetic analysis showed that at higher concentrations (>100 μ M), peptide 10 inhibited the MetAP activity (data not shown). During HPLC analysis of the MetAP reaction mixture, we observed that peptide 10 formed a complex with the Co²⁺ ion (used in MetAP assays). The peptide-metal complex had a retention time different from that of the free peptide and disappeared when a lower concentration of Co^{2+} ion was used in the assay buffer. Presumably, during library screening, the His-containing peptides inhibited the MetAP enzymes by binding to their active-site metal ion(s). Inhibition of MetAP by Met-X-His peptides had also been reported by other investigators (16).

Kinetic assays of human MetAP1 and MetAP2 against the above peptides also confirmed their specificity profiles revealed by library screening. Indeed, both human enzymes disfavor acidic residues. Replacement of a Glu at the P2' position with either Arg or His increased the catalytic activity by 2–22-fold (in Table 2, compare peptides 1, 7, and 10). Likewise, a Glu at the P4' position reduced the activity of both enzymes by 7–12-fold (compare peptides 10 and 12). Human MetAP2 is more tolerant than MetAP1 to larger P1' residues. While all of the peptides containing Ala, Gly, or Pro at the P1' position had similar activities toward the two enzymes (MetAP2:MetAP1 ratio between 0.43 and 3.7), peptides 6 and 11,

which contain a Val at the P1' position, were 2 orders of magnitude more active toward MetAP2 than MetAP1. MetAP2 also had a 16-fold higher activity than MetAP1 toward a Thr-containing peptide (peptide 5). To test whether this is a general property of MetAP2, we synthesized five additional Met-Val peptides, derived from the N-terminal sequences of human proteins sulfurtransferase, cyclophilin A, hemoglobin α chain, thioredoxin-like protein 1 (TXNL1), and attractin, which are known to undergo N-terminal methionine removal in vivo (Table 2, peptides 16-20) (37). All five peptides had $k_{\text{cat}}/K_{\text{M}}$ values in the range of 2000–10000 M⁻¹ s⁻¹ toward MetAP2 but were only poorly active toward human MetAP1 (74–200-fold lower activity). Our data suggest that these five proteins, and likely all Met-Val- and Met-Thr-containing proteins in humans, are mainly processed by MetAP2 in vivo. Previous X-ray crystal structural studies have shown that human MetAP1 has a narrower active-site cleft than MetAP2 (by ~ 1 Å), and the reduced size restricts the access of fumagillin and related compounds to the active site of MetAP1 (26). Similarly, the smaller active site of MetAP1 would sterically clash with the larger side chains of Val and Thr at the Pl' position. Finally, we tested two Trp-containing peptides (Table 2, peptides 14 and 15) to determine the effect of Trp on MetAP activities. Surprisingly, although none of the enzymes selected Trp among their most preferred substrates (Figures 1-3), both peptides (which contain a Trp at the P2' and P3' positions, respectively) were efficient substrates of human MetAP1 and MetAP2. A possible explanation for this discrepancy may be that beads displaying hydrophobic Trp-containing peptides swelled poorly in the aqueous screening buffer, rendering the peptides on these beads poorly accessible to the MetAP enzymes.

In Vivo Validation of MetAP1 and MetAP2 Substrate Specificity. To validate the in vitro substrate specificity data, we examined the removal of the N-terminal Met from phosphoglucomutase 1 (PGM1) and TXNL1 in vivo. PGM1 and TXNL1 contain N-terminal sequences of MVKIVT and MVGVKP, respectively, and are expected to be specific substrates of MetAP2. The protein BTF3L4, which has an N-terminal sequence of



FIGURE 4: Retention of the initiator methionine of TXNL1 caused by inhibition of MetAP2 by TNP-470. (a) Immunoblotting (IB) of immunoprecipitated (IP) C-terminal 3xFlag-tagged BTF3L4 protein from the HEK293T cell lysate. (b) Immunoblotting of the immunoprecipitated C-terminal 3xFlag-tagged PGM1 protein from the HEK293T cell lysate (3W, three washes with RIPA buffer; 6W, six washes with RIPA buffer). (c) Immunoblotting of the immunoprecipitated C-terminal 3xFlag-tagged BTF3L4, PGM1, and TXNL1 protein from the HEK293T cell lysate. (d and e) Immunoprecipitated C-terminal 3xFlag-tagged BTF3L4, PGM1, and TXNL1 were aliquoted for [35 S]methionine scintillation counting after incubation with MetAP reaction buffer (d) or after in vitro processing by both MetAP1 and MetAP2 (e). IV-43 or IV (10 μ M), TNP-470 or T (100 nM), or both were added for the last 4.5 h. The error bars are standard errors from two (BTF3L4 and PGM1 in panel d), three (TXNL1 in panel d) and BTF3L4 and PGM1 in panel e), or five (TXNL1 in panel e) independent experiments. N-Terminally methionine unprocessed BTF3L4, PGM1, and TXNL1 have 3, 12, and 8 methionine residues per molecule, respectively. *p = 0.02; ***p = 0.0003.

MNQEKL and is not expected to undergo N-terminal Met removal, was used as a negative control. Human embryonic kidney epithelial cell line HEK293T overexpressing C-terminally Flagtagged PGM1, TXNL1, or BTF3L4 proteins was treated with IV-43 [a specific MetAP1 inhibitor (38)] and/or TNP-470 [a specific MetAP2 inhibitor (13)] and then pulsed with $[^{35}S]$ Met to label any newly synthesized proteins. The putative substrate proteins (and control) were immunoprecipitated from the cell lysates with antibodies against the Flag tag. The partially purified proteins were then treated with recombinant MetAP1 and MetAP2 in vitro to cleave any retained N-terminal [³⁵S]Met residue, which was caused by inhibition of the cellular MetAPs. Treatment of the cells expressing TXNL1 with either TNP-470 alone or TNP-470 and IV-43 in combination, but not IV-43 alone, resulted in a 2-fold increase in the extent of N-terminal Met retention over the DMSO control (Figure 4). No significant increase in the extent of Met retention was observed for cells expressing BTF3L4 or PGM1. These results demonstrate that TXNL1 is indeed a specific substrate of MetAP2. The result with PGM1 was unexpected and may be caused by one or both of the following factors. Inspection of the structure of PGM1 shows that the retained Met would be buried in the folded protein and thus inaccessible to MetAP action (39). Alternatively, the N-terminal Met might be N-acetylated upon forced retention in cells and protected against MetAP2 in vitro. In this regard, treatment of human and mouse cells with TNP-470 resulted in the retention and acetylation of the N-terminal Met of cyclophilin A, a well-established MetAP2-specific substrate (40).

Corroboration with Literature Data. Previous studies have led to the conclusion that both bacterial and eukaryotic MetAPs

prefer small amino acids (e.g., Ala, Gly, Ser, Pro, Cys, Thr, and Val) as the P1' residue (17-25). Our results confirmed these earlier findings. Several studies demonstrated the importance of residues at positions P2' and beyond for catalytic activity (20, 21). The only systematic study of MetAP substrate specificity was conducted by Frottin et al. (25), who synthesized and assayed ~120 short peptides against E. coli MetAP1 and P. furiosus MetAP2. Their data suggest that removal of N-terminal methionine from proteins in vivo is dictated by the substrate specificity of MetAP(s). Our data for E. coli MetAP1 are largely consistent with the results of Frottin et al., but with one key difference. Frottin et al. reported that E. coli MetAP1 had poor activity against peptides containing acidic residues at positions P2'-P4'. In contrast, our library screening and kinetic analysis of individually synthesized peptides both showed that the *E. coli* enzyme prefers acidic residues at positions P2', P4', and P5'. This discrepancy is likely due to the fact that Frottin et al. employed very short peptides containing free C-termini (primarily tri- and tetrapeptides), which generally had poor activities toward the *E. coli* enzyme $(k_{cat}/K_{M} \sim 10^{2} - 10^{3} \text{ M}^{-1} \text{ s}^{-1})$. As described previously, our screening data revealed a negative correlation between the P2' and P3' positions with regard to acidic residues (i.e., the enzyme disfavors the presence of negative charges at both positions). Presumably, the negatively charged C-terminus of the peptides used in the Frottin work interfered with the binding of acidic peptides to the enzyme active site.

Proteomics analyses of TNP-470 treated cells have identified several mammalian proteins as MetAP2-specific substrates, including bovine cyclophilin A (N-terminal sequence MVNPTV) (41) and glyeraldehyde-3-phosphate dehydrogenase (MVKVGV) (41)

Table 3: Prediction of N-Terminal Met Removal in *E. coli* and Mammalian Cytoplasm

| N-terminal sequence | Met removal? | enzyme |
|-----------------------------------------------------------------------------------|------------------------------|---------------------------------------|
| | E. coli | |
| < M[ACGPS][^P] ^a < M[ACGPSTV]P < M[VT][^P] < M[DEFHIKLMNQRWY] | yes no variable no | MetAP1 MetAP1 |
| ľ | Mammalian | |
| < M[ACGPS] < M[VT][^DEP] < M[VT][DEP] < M[DEFHIKLMNQRWY] | yes yes variable no | MetAP1 and MetAP2 MetAP2 MetAP2 |

 a < M indicates that the Met is at the N-terminus of a protein. [ACGPS] indicates that the P1' residue is Ala, Cys, Gly, Pro, or Ser. [^P] indicates that Pro is excluded from position P2'.

and human thioredoxin (MVKQI) (40), SH3 binding glutamic acid rich-like protein (MVIRV) (40), and elongation factor-2 (MVNFT) (40). In vitro kinetic assays of the N-terminal peptides of these proteins confirmed that they all have activity 2 orders of magnitude higher toward MetAP2 than toward MetAP1. Thus, together with TXNL1 identified in this work, all six MetAP2specific substrates contain a Val as the P1' residue, consistent with our library screening data. One known exception is human protein 14-3-3 γ , which became incompletely processed when either normal or tumor epithelial cells were treated with siRNA specific for MetAP2 or MetAP1-specific inhibitor IV-43 (30, 42). The N-terminal sequence of this protein, MVDREQ, suggests that it is a poor substrate for both MetAP1 and MetAP2 (Table 2, entry 6). It is thus not surprising that an increase in the level of retention of its N-terminal methionine was observed upon inhibition of either MetAP1 or MetAP2, suggesting that both MetAP1 and MetAP2 are necessary to completely process its N-terminal Met.

Predicted N-Terminal Met Removal Pattern in E. coli and Human Proteomes. On the basis of the specificity data from our work and the literature (43), we make the following predictions about the N-terminal Met removal (Table 3). In E. coli, proteins containing small residues Ala, Cys, Gly, Pro, and Ser as the P1' residue and any amino acids other than Pro at the P2' position are expected to undergo complete Met cleavage. When the P1' residue is any amino acid other than Ala, Cys, Gly, Pro, Ser, Thr, or Val or if the P2' residue is Pro, the N-terminal Met is retained. When the P1' residue is Thr or Val and the P2' residue is not Pro, N-terminal Met cleavage is variable, depending on several factors such as the actual N-terminal sequence at positions P2'-P5', the level of protein expression, and the growth condition of the cell. In mammalian cells, proteins containing Ala, Cys, Gly, Pro, or Ser at the P1' position generally undergo complete N-terminal processing, catalyzed by MetAP1, MetAP2, or both. When the P1' residue is Thr or Val, the N-terminal Met removal is primarily catalyzed by MetAP2 and the extent of cleavage depends on the sequence at positions P2'-P5'. When the P2' residue is not Asp, Glu, or Pro, the N-terminal processing is expected to be complete. When Asp, Glu, or Pro is the P2' residue. Met removal is either incomplete or does not occur. It should be noted that these rules are meant to be a general guideline and occasional exceptions have been observed.

CONCLUSION

We have developed a novel peptide library method to systematically profile the sequence specificity of bacterial and human MetAPs. The results show that the specificity of MetAPs is largely dictated by the P1' residue; however, the sequence at positions P2'-P5' does have a significant effect on the extent of Met removal, especially for proteins containing less optimal P1' residues (e.g., Thr and Val). Further, we show that the primary difference between human MetAP1 and MetAP2 is their differential tolerance for Thr and Val at the Pl' position, suggesting that MetAP2 is primarily responsible for N-terminal processing of proteins that contain N-terminal Met-Val and Met-Thr sequences. This difference in substrate specificity between human MetAP1 and MetAP2 may be ultimately responsible for the unique effects of inhibitors of MetAP2 on angiogenesis. Finally, our data have permitted us to formulate a more complete set of rules for predicting the fate of the N-terminal Met of bacterial and mammalian proteins.

SUPPORTING INFORMATION AVAILABLE

Tables containing the peptide sequences selected against the three MetAP enzymes and additional figures. This material is available free of charge via the Internet at http://pubs.acs.org.

REFERENCES

- Meinnel, T., Mechulam, Y., and Blanquet, S. (1993) Methionine as translation start signal: A review of the enzymes of the pathway in *Escherichia coli. Biochimie* 75, 1061–1075.
- 2. Waller, J. P. (1963) The NH₂-terminal residue of the proteins from cell-free extract of *E. coli. J. Mol. Biol.* 7, 483–496.
- Giglione, C., Boularot, A., and Meinnel, T. (2004) Protein N-terminal methionine excision. *Cell. Mol. Life Sci.* 61, 1455–1474.
- Chang, S. P., McGary, E. C., and Chang, S. (1989) Methionine aminopeptidase gene of *Escherichia coli* is essential for cell growth. *J. Bacteriol.* 171, 4071–4072.
- Li, X., and Chang, Y.-H. (1995) Amino-terminal protein processing in Saccharomyces cerevisiae is an essential function that requires two distinct methionine aminopeptidases. Proc. Natl. Acad. Sci. U.S.A. 92, 12357–12361.
- Miller, C. G., Kukral, A. M., Miller, J. L., and Movva, N. R. (1989) pepM is an essential gene in *Salmonella typhimurium*. J. Bacteriol. 171, 5215–5217.
- Wang, W., Chai, S. C., Huang, M., He, H., Hurley, T. D., and Ye, Q. (2008) Discovery of inhibitors of *Escherichia coli* methionine aminopeptidase with the Fe(II)-form selectivity and antibacterial activity. *J. Med. Chem.* 51, 6110–6120.
- Evdokimov, A. G., Pokross, M., Walter, R. L., Mekel, M., Barnett, B. L., Amburgey, J., Seibel, W., Soper, S. J., Djung, J. F., Fairweather, N., Diven, C., Rastogi, V., Grinius, L., Klanke, C., Siehnel, R., Twinem, T., Andrews, R., and Curnow, A. (2007) Serendipitous discovery of novel bacterial methionine aminopeptidase inhibitors. *Proteins: Struct., Funct., Bioinf.* 66, 538–546.
- Jiracek, J., Liboska, R., Zakova, L., Dygas-Holz, A. M., Holz, R. C., Zertova, M., and Budesinsky, M. (2006) New pseudopeptide inhibitors for the type-1 methionine aminopeptidase from *Escherichia coli*. *J. Pept. Sci.* 12, 165–165.
- Huang, Q., Huang, M., Nan, F.-J., and Ye, Q. (2005) Metalloform-selective inhibition: Synthesis and structure-activity analysis of Mn(II)-form-selective inhibitors of *Escherichia coli* methionine aminopeptidase. *Bioorg. Med. Chem. Lett.* 15, 5386–5391.
- Griffith, E. C., Su, Z., Turk, B. E., Chen, S., Chang, Y.-H., Wu, Z., Biemann, K., and Liu, J. O. (1997) Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. *Chem. Biol.* 4, 461–471.
- Sin, N., Meng, L., Wang, M. Q. W., Wen, J. J., Bornmann, W. G., and Crews, C. M. (1997) The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. *Proc. Natl. Acad. Sci. U.S.A.* 94, 6099–6103.
- Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., and Folkman, J. (1990) Synthetic analogs of fumagillin that inhibit angiogenesis and suppress tumor-growth. *Nature* 348, 555–557.

- Yamamoto, T., Sudo, K., and Fujita, T. (1994) Significant inhibition of endothelial-cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470). *Anticancer Res.* 14, 1–3.
- 15. Abe, J., Zhou, W., Takuwa, N., Taguchi, J., Kurokawa, K., Kumada, M., and Takuwa, Y. (1994) A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene-product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial-cells. *Cancer Res.* 54, 3407–3412.
- Kendall, R. L., and Bradshaw, R. A. (1992) Isolation and characterization of the methionine aminopeptidase from porcine liver responsible for the cotranslational processing of proteins. *J. Biol. Chem.* 267, 20667–20673.
- Ben-Bassat, A., Bauer, K., Chang, S. Y., Myambo, K., Boosman, A., and Chang, S. (1987) Processing of the initiation methionine from proteins: Properties of *the Escherichia coli* methionine aminopeptidase and its gene structure. J. Bacteriol. 169, 751–757.
- Hirel, P.-H., Schmitter, J.-M., Dessen, P., Fayat, G., and Blanquet, S. (1989) Extent of N-terminal methionine excision from *Escherichia coli* proteins is governed by the side-chain length of the penultimate amino acid. *Proc. Natl. Acad. Sci. U.S.A.* 86, 8247–8251.
- Flinta, C., Persson, B., Jornvall, H., and von Heijne, G. (1986) Sequence determinants of cytosolic N-terminal protein processing. *Eur. J. Biochem.* 154, 193–196.
- Boissel, J.-P., Kasper, T. J., Shah, S. C., Malone, J. I., and Bunn, H. F. (1985) Amino-terminal processing of proteins: Hemoglobin south Florida, a variant with retention of initiator methionine and N-αacetylation. *Proc. Natl. Acad. Sci. U.S.A.* 82, 8448–8452.
- Chang, Y.-H., Teicher, U., and Smith, J. A. (1990) Purification and characterization of a methionine aminopeptidase from *Saccharo*myces cerevisiae. J. Biol. Chem. 265, 19892–19897.
- Tsunasawa, S., Stewart, J. W., and Sherman, F. (1985) Aminoterminal processing of mutant forms of yeast iso-1-cytochrome-c: The specificities of methionine aminopeptidase and acetyltransferase. *J. Biol. Chem.* 260, 5382–5391.
- Walker, K. W., and Bradshaw, R. A. (1999) Yeast methionine aminopeptidase I: Alteration of substrate specificity by site-directed mutagenesis. J. Biol. Chem. 274, 13403–13409.
- 24. Yang, G., Kirkpatrick, R. B., Ho, T., Zhang, G. F., Liang, P. H., Johanson, K. O., Casper, D. J., Doyle, M. L., Marino, J. P., Jr., Thompson, S. K., Chen, W., Tew, D. G., and Meek, T. D. (2001) Steady-state kinetic characterization of substrates and metal-ion specificities of the full-length and N-terminally truncated recombinant human methionine aminopeptidases (type 2). *Biochemistry 40*, 10645–10654.
- Frottin, F., Martinez, A., Peynot, P., Mitra, S., Holz, R. C., Giglione, C., and Meinnel, T. (2006) The proteomics of N-terminal methionine cleavage. *Mol. Cell. Proteomics* 5, 2336–2349.
- Addlagatta, A., Hu, X., Liu, J. O., and Matthews, B. W. (2005) Structural basis for the functional differences between type I and type II human methionine aminopeptidases. *Biochemistry* 44, 14741– 14749.
- Thakkar, A., Wavreille, A. S., and Pei, D. (2006) Traceless capping agent for peptide sequencing by partial Edman degradation and mass spectrometry. *Anal. Chem.* 78, 5935–5939.
- Hu, X., Dang, Y., Tenney, K., Crews, P., Tsai, C. W., Sixt, K. M., Cole, P. A., and Liu, J. O. (2007) Regulation of c-Src tyrosine kinase activity by bengamide a through inbition of methionine aminopeptidases. *Chem. Biol.* 14, 764–774.

- Wang, J. Y., Sheppard, G. S., Lou, P. P., Kawai, M., Park, C., Egan, D. A., Schneider, A., Bouska, J., Lesniewski, R., and Henkin, J. (2003) Physiologically relevant metal cofactor for methionine aminopeptidase-2 is manganese. *Biochemistry* 42, 5035–5042.
- Hu, X., Addlagatta, A., Lu, J., Matthews, B. W., and Liu, J. O. (2006) Elucidation of the function of type 1 human methionine aminopeptidase during cell cycle progression. *Proc. Natl. Acad. Sci. U.S.A. 103*, 18148–18153.
- Li, J.-Y., Chen, L.-L., Cui, Y.-M., Luo, Q.-L., Gu, M., Nan, F.-J., and Ye, Q.-Z. (2004) Characterization of full length and truncated type I human methionine aminopeptidases expressed from *Escherichia coli*. *Biochemistry* 43, 7892–7898.
- Chhabra, S. R., Parekh, H., Khan, A. N., Bycroft, B. W., and Kellam, B. (2001) A Dde-based carboxy linker for solid-phase synthesis. *Tetrahedron Lett.* 42, 2189–2192.
- Lam, K. S., Salmon, S. E., Hersh, E. M., Hruby, V. J., Kazmierski, W. M., and Knapp, R. J. (1991) A new type of synthetic peptide library for identifying ligand-binding activity. *Nature* 354, 82–84.
- 34. Furka, A., Sebestyen, F., Asgedom, M., and Dibo, G. (1991) General method for rapid synthesis of multicomponent peptide mixtures. *Int. J. Pept. Protein Res.* 37, 487–493.
- Kaiser, R., and Metzka, L. (1999) Enhancement of cyanogen bromide cleavage yields for methionyl-serine and methionyl-threonine peptide bonds. *Anal. Biochem.* 266, 1–8.
- 36. Sweeney, M. C., and Pei, D. (2003) An improved method for rapid sequencing of support-bound peptides by partial Edman degradation and mass spectrometry. *J. Comb. Chem.* 5, 218–222.
- Gevaert, K., Goethals, M., Martens, L., Van Damme, J., Staes, A., Thomas, G. R., and Vandekerckhove, J. (2003) Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. *Nat. Biotechnol.* 21, 566–569.
- Luo, Q. L., Li, J. Y., Liu, Z. Y., Chen, L. L., Li, J., Qian, Z., Shen, Q., Li, Y., Lushington, G. H., Ye, Q. Z., and Nan, F. J. (2003) Discovery and structural modification of inhibitors of methionine aminopeptidases from *Escherichia coli* and *Saccharomyces cerevisiae*. J. Med. Chem. 46, 2631–2640.
- Bond, C. S., White, M. F., and Hunter, W. N. (2001) High resolution structure of the phosphohistidine-activated form of *Escherichia coli* cofactor-dependent phosphoglycerate mutase. *J. Biol. Chem.* 276, 3247–3253.
- Warder, S. E., Tucker, L. A., McLoughlin, S. M., Strelitzer, T. J., Meuth, J. L., Zhang, Q., Sheppard, G. S., Richardson, P. L., Lesniewski, R., Davidsen, S. K., Bell, R. L., Rogers, J. C., and Wang, J. (2008) Discovery, Identification, and Characterization of Candidate Pharmacodynamic Markers of Methionine Aminopeptidase-2 Inhibition. *J. Proteome Res.* 7, 4807–4820.
 Turk, B. E., Griffith, E. C., Wolf, S., Biemann, K., Chang, Y. H., and Liu,
- Turk, B. E., Griffith, E. C., Wolf, S., Biemann, K., Chang, Y. H., and Liu, J. O. (1999) Selective inhibition of amino terminal methionine processing by TNP-470 and ovalicin in endothelial cells. *Chem. Biol.* 6, 823–833.
- Towbin, H., Bair, K. W., DeCaprio, J. A., Eck, M. J., Kim, S., Kinder, F. R., Morollo, A., Mueller, D. R., Schindler, P., Song, H. K., van Oostrum, J., Versace, R. W., Voshol, H., Wood, J., Zabludoff, S., and Phillips, P. E. (2003) Proteomics-based target identification: Bengamides as a new class of methionine aminopeptidase inhibitors. *J. Biol. Chem.* 278, 52964–52971.
- Martinetz, A., Traverso, J. A., Valot, B., Ferro, M., Espagne, C., Ephritikhine, G., Zivy, M., Giglione, C., and Meinnel, T. (2008) Extent of N-terminal modifications in cytosolic proteins from eukaryotes. *Proteomics* 8, 2809–2831.